categories: CD and Related Antigens (Human)

Mouse Monoclonal to CD19

LT19 (IgG1)

Product No.	Form	Quantity	Price
11-305-C025	purified	0.025 mg	choose region
11-305-C100	purified	0.1 mg	choose region
1B-305-C025	biotin	0.025 mg	choose region
1B-305-C100	biotin	0.1 mg	choose region
PB-305-T025	Pacific Blue™	25 tests	choose region
PB-305-T100	Pacific Blue™	100 tests	choose region
1F-305-T025	FITC	25 tests	choose region
1F-305-T100	FITC	100 tests	choose region
1P-305-T025	PE	25 tests	choose region
1P-305-T100	PE	100 tests	choose region
1A-305-T025	APC	25 tests	choose region
1A-305-T100	APC	100 tests	choose region
1Y-305-T025	PE-Dyomics 647	25 tests	choose region
1Y-305-T100	PE-Dyomics 647	100 tests	choose region
PC-305-T025	PerCP	25 tests	choose region
PC-305-T100	PerCP	100 tests	choose region

- In stock! Ready for immediate despatch

- Manufacture on order

Background

CD19 is a transmembrane glycoprotein of Ig superfamily expressed by B cells from the time of heavy chain rearrangement until plasma cell differentiation. It forms a tetrameric complex with CD21 (complement receptor type 2), CD81 (TAPA-1) and Leu13. Together with BCR (B cell antigen receptor), this complex signals to decrease B cell treshold for activation by the antigen. Besides being signal-amplifying coreceptor for BCR, CD19 can also signal independently of BCR coligation and it turns out to be a central regulatory component upon which multiple signaling pathways converge. Mutation of the CD19 gene results in hypogammaglobulinemia, whereas CD19 overexpression causes B cell hyperactivity.

Entrez Gene: 16p11.2

Specificity

The antibody LT19 reacts with CD19 (B4), a 95 kDa type I transmembrane glycoprotein (immunoglobulin superfamily) expressed on B lymphocytes and follicular dendritic cells; it is lost on plasma cells.

Immunogen

Daudi human Burkitt lymphoma cell line

Species Reactivity: Human Negative Species:	Applications: Flow Cytometry Recommended dilution:5 μg/ml Immunoprecipitation Usage note: Indicated dilutions are recommended starting points for use of this product. Working concentrations should be determined by the investigator.	General references Fujimoto M, Poe JC, Jansen PJ, Sato S, Tedder TF: CD19 amplifies B lymphocyte signal transduction by regulating Src-family protein tyrosine kinase activation. J Immunol. 1999 Jun 15;162(12):7088-94. [Abstract] [Full Text] Inabe K, Kurosaki T: Tyrosine phosphorylation of B-cell adaptor for phosphoinositide 3-kinase is required for Akt activation in response to CD19 engagement. Blood. 2002 Jan 15;99(2):584-9. [Abstract] [Full Text] van Zelm MC, Reisli I, van der Burg M, Castaño D, van Noesel CJ, van Tol MJ, Woellner C, Grimbacher B, Patiño PJ, van Dongen JJ, Franco JL: An antibody-deficiency syndrome due to mutations in the CD19 gene. N Engl J Med. 2006 May 4;354(18):1901-12. [Abstract] [Full Text] Shi X, Xie C, Chang S, Zhou XJ, Tedder T, Mohan C: CD19 hyperexpression augments Sle1-induced humoral autoimmunity but not clinical nephritis. Arthritis Rheum. 2007 Sep;56(9):3057-69. [Abstract] Product Specific References Elias F, Flo J, Lopez RA, Zorzopulos J, Montaner A, Rodriguez JM: Strong cytosine-guanosine-independent immunostimulation in humans and other primates by synthetic oligodeoxynucleotides with PyNTTTTGT motifs. J Immunol. 2003 Oct 1;171(7):3697-704. [Abstract] [Full Text] Lin CW, Liu TY, Chen SU, Wang KT, Medeiros LJ, Hsu SM: CD94 1A transcripts characterize lymphoblastic lymphoma/leukemia of immature natural killer cell origin with distinct clinical features. Blood. 2005 Nov 15;106(10):3567-74. Epub 2005 Jul 26. [Abstract] [Full Text]

Species Reactivity:

Human

Negative Species:

Applications:

Flow Cytometry
Recommended dilution:5 μg/ml
Immunoprecipitation

Usage note:
Indicated dilutions are recommended starting points for use of this product. Working concentrations should be determined by the investigator.

General references

*Fujimoto M, Poe JC, Jansen PJ, Sato S, Tedder TF: CD19 amplifies B lymphocyte signal transduction by regulating Src-family protein tyrosine kinase activation. J Immunol. 1999 Jun 15;162(12):7088-94. [Abstract] [Full Text]

*Inabe K, Kurosaki T: Tyrosine phosphorylation of B-cell adaptor for phosphoinositide 3-kinase is required for Akt activation in response to CD19 engagement. Blood. 2002 Jan 15;99(2):584-9. [Abstract] [Full Text]

*van Zelm MC, Reisli I, van der Burg M, Castaño D, van Noesel CJ, van Tol MJ, Woellner C, Grimbacher B, Patiño PJ, van Dongen JJ, Franco JL: An antibody-deficiency syndrome due to mutations in the CD19 gene. N Engl J Med. 2006 May 4;354(18):1901-12. [Abstract] [Full Text]

*Shi X, Xie C, Chang S, Zhou XJ, Tedder T, Mohan C: CD19 hyperexpression augments Sle1-induced humoral autoimmunity but not clinical nephritis. Arthritis Rheum. 2007 Sep;56(9):3057-69. [Abstract]

Product Specific References

*Elias F, Flo J, Lopez RA, Zorzopulos J, Montaner A, Rodriguez JM: Strong cytosine-guanosine-independent immunostimulation in humans and other primates by synthetic oligodeoxynucleotides with PyNTTTTGT motifs. J Immunol. 2003 Oct 1;171(7):3697-704. [Abstract] [Full Text]

*Lin CW, Liu TY, Chen SU, Wang KT, Medeiros LJ, Hsu SM: CD94 1A transcripts characterize lymphoblastic lymphoma/leukemia of immature natural killer cell origin with distinct clinical features. Blood. 2005 Nov 15;106(10):3567-74. Epub 2005 Jul 26. [Abstract] [Full Text]

For research use only. Not for drug, diagnostic or other use.

Related Products

Mouse IgG1 Isotype Control

Example Data

Fig. 1. Flow Cytometry analysis

Fig. 1. Surface staining of human peripheral blood cells with anti-human CD19 (LT19) APC.

PRODUCTS